Bonacorda Jeffrey 4

What Happened Jeffrey Bonacorda, VP Finance & Controller of Kazia Therapeutics (KZIA), was granted 150,000 stock options over ADSs on January 8, 2026. The options were granted for no cash consideration with an exercise price of $6.78 per ADS (implied cost to exercise all options = $1,017,000) and expire on January 8, 2029. This is an award (derivative grant), not a purchase or sale of underlying shares.

Key Details

• Transaction date: January 8, 2026; Form filed July 8, 2026 (filing appears late).
• Grant type: 150,000 options over ADSs; exercise price $6.78 per ADS; grant approved by the Remuneration Committee.
• Vesting: 1/3 vests on January 8, 2027 (Commencement Date); remaining 2/3 vest in equal yearly tranches on each anniversary of the Commencement Date.
• Expiration: January 8, 2029.
• Consideration: options granted for no consideration (acquisition price reported $0.00).
• Shares owned after transaction: not specified in the filing.

Context

• This was a derivative award (stock options), not an immediate cash transaction or sale. Options give the holder the right to buy ADSs later at $6.78 each if and when vested.
• Because the Form 4 was filed about six months after the grant date, the filing is late; late filings can reduce transparency for investors but do not themselves indicate the insider's intent.